Propanc Biopharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
Mailing Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
Phone
61-03-9882-0780
Fiscal Year End
0630
EIN
330662986
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| S-1/A IPO registration amendment | February 19, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 17, 2026 | View on SEC |
| S-1 IPO registration statement | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| S-1 IPO registration statement | December 30, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 10, 2025 | View on SEC |
| 8-K Current report of material events | October 14, 2025 | View on SEC |
Annual Reports
10-K
September 29, 2025
- Approved for new clinical trial in Australia.
- Early lab results suggest PRP might block cancer spread.
Material Events
8-K
Financial Distress
January 7, 2026
High Impact
- Propanc Biopharma, Inc. received a notice from Nasdaq for its stock price falling below the required minimum of $1.00 per share.
- The company is at risk of being delisted from The Nasdaq Capital Market if it doesn't regain compliance.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.